Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines contain...

Descripción completa

Detalles Bibliográficos
Autores principales: Galgani, Ilaria, Põder, Airi, Jõgi, Rain, Anttila, Veli-Jukka, Milleri, Stefano, Borobia, Alberto M., Launay, Odile, Testa, Marco, Casula, Daniela, Grassano, Luca, Tasciotti, Annaelisa, Dozot, Marie, Arora, Ashwani K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Novel Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/
https://www.ncbi.nlm.nih.gov/pubmed/36974988
http://dx.doi.org/10.1080/21645515.2023.2187194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/
https://www.ncbi.nlm.nih.gov/pubmed/36974988
http://dx.doi.org/10.1080/21645515.2023.2187194

Ejemplares similares